[go: up one dir, main page]

MX2019004992A - Sacubitril valsartán trisódico amorfo y proceso para su preparacion. - Google Patents

Sacubitril valsartán trisódico amorfo y proceso para su preparacion.

Info

Publication number
MX2019004992A
MX2019004992A MX2019004992A MX2019004992A MX2019004992A MX 2019004992 A MX2019004992 A MX 2019004992A MX 2019004992 A MX2019004992 A MX 2019004992A MX 2019004992 A MX2019004992 A MX 2019004992A MX 2019004992 A MX2019004992 A MX 2019004992A
Authority
MX
Mexico
Prior art keywords
methyl
crystalline form
preparation
present
provides
Prior art date
Application number
MX2019004992A
Other languages
English (en)
Inventor
Venkata Raghavendra Charyulu Palle
Rameshchandra Patel Pratik
Devaiah Venu Thirunelimada
Avathu Vidyasagar Reddy
Shanmughasamy Rajmahendra
Original Assignee
Biocon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Ltd filed Critical Biocon Ltd
Publication of MX2019004992A publication Critical patent/MX2019004992A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/51—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona la Forma B1 cristalina de sal sodio de éster etílico del ácido N-(3-carboxil-l-oxopropil)-(4S)-( p- fenilfenilmetil)-4-amino-2R-metil butanoico, la Forma B2 cristalina de sal sodio de éster etílico del ácido N-(3-carboxil-1 -oxopropil)-(4S)-(pfenilfenilmetil)-4-amino-2R-met il butanoico, y un nuevo proceso para la preparación de la Forma B cristalina B de sal sodio de éster etílico del ácido N-(3-carboxil-l-xopropil)-(4S)-(p-fenilfenilmetil)-4-amino-2R- metil butanoico. La presente invención también proporciona la Forma B cristalina de sal disodio de (S)-N-(1-carboxi-2-metil-prop -1-i1)-Npentanoil-N42'-(1H-tetrazol-5-i1)-bifenil-4-il-metil]-ami na, la Forma P cristalina sal disodio de (S)-N-(1-carboxi-2-metil- prop-1-i1)-N-pentanoilN-[2'-(1H-tetrazol-5-i1)-bifenil-4-il-metil ]-amina y procesos para su preparación. La presente invención proporciona además un método industrial de producción de la Forma amorfa de sacubitril valsartán trisódico. La presente invención también proporciona dispersiones sólidas amorfas de sacubitril valsartán trisódico con excipientes.
MX2019004992A 2016-10-28 2017-10-28 Sacubitril valsartán trisódico amorfo y proceso para su preparacion. MX2019004992A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN201641037145 2016-10-28
IN201641038689 2016-11-11
IN201641043910 2016-12-22
PCT/IB2017/056706 WO2018078592A1 (en) 2016-10-28 2017-10-28 Amorphous trisodium sacubitril valsartan and process for its preparation

Publications (1)

Publication Number Publication Date
MX2019004992A true MX2019004992A (es) 2020-02-26

Family

ID=62024497

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004992A MX2019004992A (es) 2016-10-28 2017-10-28 Sacubitril valsartán trisódico amorfo y proceso para su preparacion.

Country Status (10)

Country Link
US (2) US10995060B2 (es)
EP (1) EP3532454A4 (es)
JP (1) JP7022747B2 (es)
KR (1) KR20190077467A (es)
AU (1) AU2017349757A1 (es)
BR (1) BR112019008581A2 (es)
CA (1) CA3041962A1 (es)
MX (1) MX2019004992A (es)
RU (1) RU2019115782A (es)
WO (1) WO2018078592A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3522886A4 (en) * 2016-10-10 2020-02-19 Laurus Labs Limited STABLE AMORPHE FORM OF THE SACUBITRIL VALSARTAN TRINATRIUM COMPLEX AND METHOD FOR THE PRODUCTION THEREOF
EP3840746A1 (en) 2018-08-23 2021-06-30 Novartis AG New pharmaceutical use for the treatment of heart failure
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217996A (en) 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
CN1216873C (zh) 2000-07-19 2005-08-31 诺瓦提斯公司 缬沙坦的盐
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
CN105461647B (zh) 2014-09-28 2018-06-29 四川海思科制药有限公司 缬沙坦沙库比曲三钠盐复合物的固态形式及其制备方法和用途
PT3218351T (pt) 2014-11-14 2019-09-26 Zentiva Ks Um método para a preparação, isolamento e purificação de formas farmaceuticamente aplicáveis de ahu-377
CN105693543B (zh) 2014-12-15 2018-08-10 四川海思科制药有限公司 沙库比曲类衍生物、其药物组合物、制备方法及用途
CN105837464A (zh) 2015-01-15 2016-08-10 四川海思科制药有限公司 沙库比曲钠的晶型及其制备方法和用途
EP3253740A1 (en) 2015-02-06 2017-12-13 Mylan Laboratories Ltd. Amorphous trisodium sacubitril valsartan and a process for the preparation thereof
WO2016135751A1 (en) 2015-02-25 2016-09-01 Mylan Laboratories Limited Novel process for the preparation of sacubitril and its intermediates
WO2017097275A1 (en) 2015-12-11 2017-06-15 Zentiva, K.S. Solid forms of (2r,4s)-5-(biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2- -methylpentanoic acid ethyl ester, its salts and a preparation method
CN105503638A (zh) 2016-01-13 2016-04-20 浙江天宇药业股份有限公司 沙库比曲二环己胺盐、晶型及其制备方法

Also Published As

Publication number Publication date
JP7022747B2 (ja) 2022-02-18
RU2019115782A (ru) 2020-11-30
KR20190077467A (ko) 2019-07-03
CA3041962A1 (en) 2018-05-03
US10995060B2 (en) 2021-05-04
US11629120B2 (en) 2023-04-18
US20190322615A1 (en) 2019-10-24
BR112019008581A2 (pt) 2019-09-17
AU2017349757A1 (en) 2019-05-30
US20210122708A1 (en) 2021-04-29
EP3532454A1 (en) 2019-09-04
EP3532454A4 (en) 2020-11-25
RU2019115782A3 (es) 2021-06-17
JP2020503257A (ja) 2020-01-30
WO2018078592A1 (en) 2018-05-03

Similar Documents

Publication Publication Date Title
JOP20180113B1 (ar) مركبات بيريميدين -2-يل امينو -h1- بيرازول كمثبطات lrrk2 للاستخدام في علاج اضطرابات تنكسية عصبية
MX2018001491A (es) Metodos para la preparacion de acidos biliares y derivados de los mismos.
WO2016130920A3 (en) Lrrk2 inhibitors and methods of making and using the same
PH12018500777A1 (en) Farnesoid x receptor modulators
MX2018007129A (es) Formas solidas de ester etilico del acido (2r,4s)-5-(bifenil-4-il) -4-[(3-carboxipropionil)amino]-2-metil-pentanoico, sus sales y un metodo de preparacion.
MX384800B (es) Derivado de 3-desoxi y composiciones farmaceuticas del mismo.
JOP20200059A1 (ar) مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها
MX2018003649A (es) Metodos e intermedios para la preparacion de derivados de acido biliar.
SG11201811835YA (en) Diorganylphosphinic acid salts, method for the production thereof and the use thereof
TN2014000058A1 (en) A Novel 1,2,3,4-Tetrahydroquinoline Derivative Useful for the Treatment of Diabetes
BR112019001980A2 (pt) inibidor de ido1 e método de preparação e aplicação do mesmo
ZA201805790B (en) Improved process for the preparation of osimertinib (azd9291) or a salt thereof, and "azd9291 aniline" or a salt thereof
SG11201906688VA (en) Novel ester compounds, method for the production thereof and use thereof
HK1199025A1 (en) Benzyl sulfonamide derivatives useful as mogat - 2 inhibitors
AU2016237099B2 (en) Method for producing novel nitrogen-containing compound or salt thereof, and production intermediate of same
SG10201806830RA (en) Preparation of N,N-(di)alkylaminoalkyl(meth)acrylamide or N,N-(di)alkylaminoalkyl (meth)acrylate and the quaternary ammonium salts thereof as flocculating aids and gelling agents
MX2019004992A (es) Sacubitril valsartán trisódico amorfo y proceso para su preparacion.
PH12017501397A1 (en) (2s, 4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor
SG11201810725WA (en) Novel β-lactamase inhibitors
PH12016502568B1 (en) Novel heterocyclic compound
WO2016142819A3 (en) Novel process for the preparation of ranolazine
MX2018000459A (es) Metodo para la fabricacion de compuestos heterociclicos que contienen nitrogeno y compuestos intermediarios de los mismos.
MX2019011261A (es) Compuestos de isoxazol carboxamida y sus usos.
WO2017034242A3 (ko) 신규한 카테콜 유도체 및 이를 포함하는 약학적 조성물
MX2017002790A (es) Sal de un derivado de cefalosporina, forma solida cristalina del mismo y metodo para su produccion.